Table 1 Descriptive statistics of the study population (men diagnosed with Prostate Cancer in AMORIS) (n = 11,492)
From: Can pre-diagnostic serum levels of sodium and potassium predict prostate cancer survival?
Sodium (mEq/L) Mean = 140.71 (SD = 2.92) | Potassium (mEq/L) Mean = 4.26 (SD = 0.33) | |||||
|---|---|---|---|---|---|---|
< 136 (n = 255) | 136–145 (n = 10,584) | > 145 (n = 653) | < 3.5 (n = 47) | 3.5–5 (n = 11,268) | > 5 (n = 177) | |
Mean age (yrs.) (SD) | 69.7 (8.3) | 69.5 (8.1) | 69.4 (8.0) | 70.4 (8.5) | 69.5 (8.1) | 70.7 (8.6) |
Socio-economic status (%) | ||||||
White collar | 152 (59.61) | 7145 (67.51) | 455 (69.68) | 29 (61.7) | 7609 (67.53) | 114 (64.41) |
Blue collar | 85 (33.33) | 2903 (27.43) | 169 (25.88) | 17 (36.17) | 3095 (27.47) | 45 (25.42) |
Unemployed/missing | 18 (7.06) | 536 (5.06) | 29 (4.44) | 1 (2.13) | 564 (5.01) | 18 (10.17) |
Education (%) | ||||||
Low | 78 (30.59) | 2782 (26.28) | 178 (27.26) | 18 (38.29) | 2979 (26.44) | 41 (23.16) |
Middle | 102 (0.4) | 4323 (40.84) | 257 (39.36) | 17 (36.17) | 4584 (40.68) | 81 (45.76) |
High | 152 (59.61) | 3137 (29.64) | 202 (30.93) | 11 (23.4) | 3351 (29.74) | 46 (25.99) |
Missing | 6 (2.35) | 342 (3.23) | 16 (2.45) | 1 (2.13) | 354 (3.14) | 9 (5.08) |
Charslon Co-morbidity Index (%) | ||||||
0 | 160 (62.74) | 6947 (65.64) | 435 (66.62) | 28 (59.57) | 7411 (65.77) | 103 (58.19) |
1 | 37 (14.51) | 1464 (13.83) | 84 (12.86) | 10 (21.28) | 1544 (13.7) | 31 (17.51) |
2 | 33 (12.94) | 1325 (12.52) | 84 (12.86) | 7 (14.89) | 1414 (12.55) | 21 (11.86) |
3+ | 25 (9.80) | 848 (8.01) | 50 (7.66) | 2 (4.26) | 899 (7.98) | 22 (12.43) |
Body mass index (kg/m2) (%) | ||||||
< 18.5 | – | 9 (0.08) | – | – | 9 (0.08) | – |
18.5–24.99 | 28 (10.98) | 919 (8.68) | 62 (9.49) | 4 (8.51) | 989 (8.78) | 16 (9.04) |
25–29.99 | 20 (7.84) | 932 (8.80) | 55 (8.42) | 5 (10.64) | 991 (8.79) | 11 (6.21) |
> = 30 | 5 (1.96) | 195 (1.84) | 11 (1.68) | 1 (2.13) | 208 (1.84) | 2 (1.13) |
Missing | 202 (79.21) | 8529 (80.58) | 525 (80.39) | 37 (78.72) | 9071 (80.5) | 148 (83.61) |
Creatinine (micromol/L) | ||||||
Mean (SD) | 89.39 (16.47) | 89.80 (18.95) | 91.66 (12.47) | 90.89 (15.29) | 89.63 (13.49) | 106.98 (103.33) |
Missing (%) | 1 (0.39) | 59 (0.56) | 2 (0.31) | 0 | 59 (0.52) | 3 (1.69) |
Interval time (years) | ||||||
Mean (SD) | 13.3 (6.6) | 13.2 (6.3) | 14.3 (5.9) | 11.3 (7.2) | 13.3 (6.3) | 12.1 (6.6) |
Cancer severity (%) | ||||||
Low risk | 49 (19.21) | 2337 (22.08) | 157 (24.04) | 12 (25.53) | 2493 (22.12) | 38 (21.47) |
Intermediate risk | 50 (19.61) | 2299 (21.72) | 139 (21.29) | 9 (19.15) | 2445 (21.69) | 34 (19.21) |
High risk | 46 (18.04) | 1917 (18.11) | 109 (16.69) | 7 (14.89) | 2035 (18.06) | 30 (16.95) |
Regionally metastatic | 14 (5.49) | 511 (4.83) | 38 (5.82) | – | 559 (4.96) | 4 (2.26) |
Distant metastases | 20 (7.84) | 814 (7.69) | 56 (8.57) | 3 (6.38) | 870 (7.72) | 17 (9.6) |
Missing | 76 (29.80) | 2706 (25.57) | 154 (23.58) | 16 (34.04) | 2866 (25.43) | 54 (30.51) |